Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Drospirenone/Ethinyl Estradiol with HS-10374
NCT07181343Phase 1Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-10374 in psoriasis, sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Plasma Concentration (Cmax) of Drospirenone and Ethinyl Estradiol, Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) and 2 more. Started May 2025; status: completed.
02
Drugs
HS-10374
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT07181343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181343.